How is EQ-5D data analysed in clinical trials?

With EQ-5D increasingly used in economic evaluations, findings in this systematic review highlight an urgent need for better guidance & standardisation in statistical approaches.

A must-read for trialists, health economists, and HTA professionals 👇

Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States - PharmacoEconomics Objective Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HI...

CEVR is thrilled to announce the winners of our 7th Annual Cost-Effectiveness Paper of the Year Award.

Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)

#CEA #HEOR

Statistical Methods for Analyzing EQ-5D in Randomized Clinical Trials: A Systematic Literature Review We conducted a systematic literature review to summarize the application of statistical methods for analyzing treatment effect on EQ-5D in randomized clinical trials (RCTs).

The EQ-5D has been commonly collected in many randomized clinical trials. However, it is not clear how it has been analyzed and reported. This systematic review focuses on how EQ-5D data were analyzed to estimate treatment effect in these trials. www.valueinhealthjournal.com/article/S109...

Medicare’s Drug Price Negotiation And Innovation: What’s Off The Table Matters Too | Health Affairs Forefront Certain exemptions from the Medicare drug price negotiation program could have unintended consequences on pharmaceutical innovation, particularly for small biotech companies and patients with rare diseases.

Exemptions from the Medicare drug price negotiation program could have unintended consequences on pharmaceutical innovation, particularly for small biotech companies and patients with rare diseases. www.healthaffairs.org/do/10.1377/f...

@dano-hta.bsky.social thank Dan for sharing!

The Real Reasons Drug Prices Are So High | Health Affairs Forefront Key policies introduced over the past 45 years have brought new research organizations and investors into the pharmaceutical R&D process, increasing industry’s market power relative to that of private...

“The ‘new’ R&D ecosystem has given us some very effective drugs, but it has also become a machine converting money from patients, employers, and taxpayers into private wealth.”

A brilliant, must-read piece if you are interested in drug pricing!
www.healthaffairs.org/content/fore...

Curious about whether numeracy has any impact?